Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.

Slides:

Advertisements

Similar presentations

Memorial Sloan-Kettering Cancer Center

Advertisements

Is Radical Prostatectomy Adequate For High Risk Prostate Cancer?

NPCA data collection on men undergoing radical surgery for prostate cancer Paul Cathcart, NPCA Urology Project Coordinator.

PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.

Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.

Carcinoma of the Prostate By: Ishan Parikh. Background on Cancer  Oldest information dates back to 3000 BC, Egyptian textbook on trauma surgery – “There.

Stephen Ko, M.D. Mayo Clinic Jacksonville

In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.

Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.

Prostate Cancer Cancer: Cancer is a term used for diseases in which abnormal cells divide without control and are able to invade other tissues. Cancer.

Steven Joniau Filip Ameye

Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.

© Cancer Research UK 2008 Registered charity number Prostate cancer – UK December 2009.

Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma

Prostate cancer: To screen or not to screen – To treat or not to treat Dr Oliver Klein – Medical Oncologist.

Modern Management of Prostate Cancer With Active Surveillance PROSTATE CANCER SYMPOSIUM NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE SEPTEMBER 10,

Howard M. Sandler, MD University of Michigan Medical School

Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,

Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.

Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.

Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.

Prostate Cancer Treatment: What’s Best For You?

Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.

Robert Dreicer, M.D., M.S., FACP Chair Dept of Solid Tumor Oncology

Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.

on behalf of the ACOSOG Z4032 Investigators

Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.

Prostate Cancer Screening Risk Management Ben Inch.

Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.

1 Prostate Cancer. 2 Prostate Gland Muscular Walnut-sized gland Makes seminal fluid Muscles contract to push semen through the urethra Located directly.

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

South West Public Health Observatory The changing casemix of prostate cancer patients and prostatectomies in the South West Sean McPhail.

Prostatectomy operations in England South West Public Health Observatory Trends in the use of radical prostatectomy in England Sean McPhail.

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.

Reducing Tobacco Intake Lowers Risk of Lung Cancer in Heavy Smokers Slideset on: Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung.

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,

Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital.

Journal Club August 10, 2012 Ryan M. Zitnay MD. Case 71 y/o male veteran w PMH CAD s/p MI, HTN, HL, constipation Followed by urology for rising PSA x.

Philipp Dahm, Ari D. Silverstein, Alon Z

Surgical Treatment in Locally Advanced Prostate Cancer

STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

Bladder Cancer and Prostatic Cancer

Nat. Rev. Urol. doi: /nrurol

Decipher Prostate, Decipher Bladder and Decipher GRID

New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.

Prostate cancer mortality as a factor of Gleason score and age at diagnosis in men managed conservatively. (Adapted, with permission, from Albertsen PC.

Prognosis of younger patients in non-small cell lung cancer

Post Op Positive Seminal Vesicle Case 4: Prostate_4

Prostate Cancer: Highlights from 2006

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Apollo Gleneagles Hospitals,

Volume 60, Issue 6, Pages (December 2011)

Volume 67, Issue 2, Pages (February 2015)

What is New in Hormone Therapy for Prostate Cancer in 2007?

Volume 67, Issue 6, Pages (June 2015)

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Volume 58, Issue 1, Pages 1-7 (July 2010)

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Antonio Alcaraz, Pierre Teillac European Urology Supplements

Long-Term Hormonal Therapy: Who Would Benefit?

Patient characteristics: American vs Canadian transplant patients

Axel Heidenreich European Urology Supplements

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Fernando P. Secin, Fernando J. Bianco, Nicholas T

Axel Heidenreich European Urology Supplements

Presentation transcript:

Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:

clinicaloptions.com/onco Oncology Journal Options Freedland S, et al. JAMA. 2005;294: Background and Rationale  Biochemical relapse (prostate-specific antigen [PSA]  0.2 ng/mL) after radical prostatectomy may presage future metastasis  Improved risk-assessment models needed for refining patient management  Previous cohort analysis evaluated risk of metastasis after rising PSA (n = 304) –Median time from biochemical recurrence to metastasis: 8 years –Median time from metastasis to death: 5 years

clinicaloptions.com/onco Oncology Journal Options Freedland S, et al. JAMA. 2005;294: Baseline Characteristics CharacteristicEligible Patients, n (%) Race  White  Black  Other 360 (95) 14 (4) 5 (1) Gleason score  2-6  7  (14) 195 (51) 130 (34) Extraprostatic spread  Surgical margins  Extracapsular confines  Seminal vesicle  Lymph nodes 178 (47) 337 (89) 143 (38) 124 (33) Postrecurrence PSA doubling time  < 3 mos  ≥ 3 mos 23 (6) 356 (94)

clinicaloptions.com/onco Oncology Journal Options Freedland S, et al. JAMA. 2005;294: Main Findings  Mean time from surgery to biochemical recurrence: 3.5 years  Overall prostate cancer–specific survival from time of biochemical recurrence –5 year: 93% (95% confidence interval [CI]: 90%-96%) –10 year: 73% (95% CI: 66%-79%) –15 year: 55% (95% CI: 41%-67%)

clinicaloptions.com/onco Oncology Journal Options Freedland S, et al. JAMA. 2005;294: Main Findings (cont’d)  High-risk indicators for prostate cancer–specific mortality –Short PSA doubling time (< 3 months) –Gleason score of 8-10 –Time from surgery to biochemical recurrence ≤ 3 years Risk FactorsHazard Ratio (95% CI)P Value PSA doubling time (< 3 mos vs  15 mos) 27.5 ( )<.001 Years from surgery to relapse (  3 vs > 3) 3.5 ( ).002 Gleason score (≥ 8 vs < 8)2.3 ( ).002

clinicaloptions.com/onco Oncology Journal Options Freedland S, et al. JAMA. 2005;294: Key Conclusions  Select clinical variables helpful in establishing prostate cancer – specific mortality risk in patients with biochemical recurrence after radical prostatectomy –PSA doubling time –Gleason score –Time from surgery to biochemical recurrence  High-risk patients may consequently be identified for early, more aggressive treatment options